These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38757292)

  • 1. Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset.
    Ciciriello S; Littlejohn GO; Treuer T; Gibson KA; Haladyj E; Youssef P; Bird P; O'Sullivan C; Smith T; Deakin CT
    Clin Exp Rheumatol; 2024 Sep; 42(9):1763-1772. PubMed ID: 38757292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
    Fitton J; Melville AR; Emery P; Nam JL; Buch MH
    Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Takeuchi T; Yoshikawa A; Katayama M; Yamamoto K; Okita Y; Hirao M; Etani Y; Kumanogoh A; Okada S; Nakata K
    Sci Rep; 2022 Jan; 12(1):134. PubMed ID: 34997059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis.
    Saito K; Yoshida S; Ebina H; Miyata M; Suzuki E; Kanno T; Sumichika Y; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    PLoS One; 2024; 19(7):e0306714. PubMed ID: 38990897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
    Scheepers L; Yang Y; Chen YL; Jones G
    Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study.
    Chen PK; Chang SH; Chen YM; Chen HH; Huang PH; Huang CC; Yeo KJ; Lan JL; Chen DY
    Clin Rheumatol; 2024 Aug; 43(8):2503-2511. PubMed ID: 38954278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
    Aymon R; Mongin D; Bergstra SA; Choquette D; Codreanu C; De Cock D; Dreyer L; Elkayam O; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Koca SS; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rodrigues A; Rotar Z; Strangfeld A; Verschueren P; Westermann R; Zavada J; Courvoisier DS; Finckh A; Lauper K
    Ann Rheum Dis; 2024 Mar; 83(4):421-428. PubMed ID: 38071508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis.
    Ouranos K; Avila DV; Mylona EK; Vassilopoulos A; Vassilopoulos S; Shehadeh F; Mylonakis E
    PLoS One; 2024; 19(7):e0306548. PubMed ID: 39083492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.
    Opdam MAA; Broeder ND; van den Bemt BJF; Mulder K; van de Wiel KM; van Ballegooijen H; van Crevel R; den Broeder AA
    Clin Rheumatol; 2024 Jun; 43(6):2133-2138. PubMed ID: 38703283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature.
    Loricera J; Tofade T; Prieto-Peña D; Romero-Yuste S; de Miguel E; Riveros-Frutos A; Ferraz-Amaro I; Labrador E; Maiz O; Becerra E; Narváez J; Galíndez-Agirregoikoa E; González-Fernández I; Urruticoechea-Arana A; Ramos-Calvo Á; López-Gutiérrez F; Castañeda S; Unizony S; Blanco R
    Arthritis Res Ther; 2024 Jun; 26(1):116. PubMed ID: 38840219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
    Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Inoue Y; Fujino Y; Tanaka Y
    Ann Rheum Dis; 2021 Sep; 80(9):1130-1136. PubMed ID: 33827788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
    Hernández-Cruz B; Otero-Varela L; Freire-González M; Busquets-Pérez N; García González AJ; Moreno-Ramos M; Blanco-Madrigal JM; Manrique-Arija S; Perez-Pampin E; Ruiz-Montesino D; Sánchez-Alonso F; Sanchez-Piedra C; Castrejón I;
    Ann Rheum Dis; 2024 Aug; 83(9):1189-1199. PubMed ID: 38594056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse reactions to Janus kinase inhibitors: Study of their incidence and predictive factors in patients with rheumatoid arthritis.
    Martinez-Molina C; Guardiola Tey JM; Ruiz-Ramos J; Feliu A; Puig-Campmany M; Vidal S; Corominas H
    Med Clin (Barc); 2024 Oct; 163(8):391-396. PubMed ID: 39003114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK inhibitors in the treatment of adult patients with juvenile idiopathic arthritis: a retrospective monocentric experience.
    Chighizola CB; Pellico MR; Pandolfi M; Marelli L; Cornalba M; Pontikaki I; Costi S; Gattinara M; Marino A; Miserocchi E; Caporali R
    Clin Exp Rheumatol; 2024 May; 42(5):974-982. PubMed ID: 38530666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
    Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of janus kinase inhibitors in the treatment of rheumatic diseases].
    Krüger K
    Internist (Berl); 2019 Nov; 60(11):1215-1220. PubMed ID: 31486859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network.
    Strunz PP; Englbrecht M; Risser LM; Witte T; Froehlich M; Schmalzing M; Gernert M; Schmieder A; Bartz-Bazzanella P; von der Decken C; Karberg K; Gauler G; Wurth P; Späthling-Mestekemper S; Kuhn C; Vorbrüggen W; Heck J; Welcker M; Kleinert S
    Rheumatol Int; 2024 Oct; 44(10):2057-2066. PubMed ID: 39136784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of Janus Kinase inhibitor selectivity.
    Choy EH
    Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
    Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
    BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.